Search
News
Emese Zsiros, MD, PhD, to Lead Gynecologic Oncology Program at Roswell Park
… Emese Zsiros, MD, PhD, to Lead Gynecologic Oncology Program at … Park Comprehensive Cancer Center has promoted Emese Zsiros, MD, PhD, FACOG , to lead its Department of … Oncology. On staff at Roswell Park since 2014, Dr. Zsiros, an accomplished physician-researcher, will also hold …
News
Roswell Park Study: Chronic Opioid Use Reduced by Limiting Prescribed Opioids After Surgery
… use,” appears today in JAMA Oncology . It was led by Emese Zsiros, MD, PhD , the Shashi Lele, MD, Endowed Chair and … (from 6.1% pre-protocol to 2.7% post-protocol). Dr. Zsiros and her team relied on New York State’s rigorous … when post-surgical pain would no longer be an issue. Dr. Zsiros notes that data from the Centers for Disease Control …
News
Roswell Park Team Identifies Factors That Boost Effectiveness of Immunotherapy in Recurrent Ovarian Cancer
… of Immunotherapy in Recurrent Ovarian Cancer Dr. Emese Zsiros leads work exploring interactions of tumor, … treatment options. The study’s senior author, Emese Zsiros, MD, PhD, FACOG , Chair of Gynecologic Oncology and … that does not respond to platinum-based treatments. Dr. Zsiros and her colleagues took the results a step further in …
News
Roswell Park Team Assesses Addition of Complement Inhibitor Drug to Immunotherapy for Ovarian Cancer
… it has been evaluated for the treatment of cancer. Emese Zsiros, MD, PhD, FACOG , serves as principal investigator for … Research Project Grant (R01) awarded to Drs. Zsiros and Segal. “The tumor microenvironment of ovarian … cancer strongly suppresses the immune system,” says Dr. Zsiros, who is Chair of the Department of Gynecologic …
News
Roswell Park Researchers Uncover Clues to Immunotherapy Response in Patients with Recurrent Ovarian Cancer
… which grew out of a phase 2 clinical trial led by Emese Zsiros, MD, PhD, FACOG , Chair and Director of Research, … can quickly age a patient’s immune system,” explains Dr. Zsiros, a gynecologic oncologist and senior author on the new … due to the weakened state of patients’ immune systems. Dr. Zsiros and team hypothesized that the varied responses …
Clinical Trial
A Phase I First-In-Human, Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors
… SIM0505 in Adult Participants with Advanced Solid Tumors I Zsiros, Emese This is an open-label, multicenter phase 1 …
Clinical Trial
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY FOR LNCB74, A B7-H4 TARGETED ANTIBODY DRUG CONJUGATE, AS MONOTHERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
… MONOTHERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS I Zsiros, Emese This is an open-label, phase 1, dose escalation …
News
Roswell Park Community Comes Together to Celebrate Outstanding Physicians
… a robotic approach to pancreaticoduodenectomy.” Emese Zsiros, MD, PhD, FACOG — Breaking Barriers Award for Visionary Leadership Dr. Zsiros, Chair of Gynecologic Oncology and the Shashi Lele, … status quo, and leads with clarity and courage. “Dr. Emese Zsiros has a rare and remarkable ability to transform vision …
Clinical Trial
Randomized Phase 2 Clinical Trial of Pembrolizumab Combined with Bevacizumab with or without Agonist Anti-CD40 CDX-1140 in Patients with Recurrent Ovarian Cancer
… CDX-1140 in Patients with Recurrent Ovarian Cancer II Zsiros, Emese This phase II trial tests whether pembrolizumab …
Clinical Trial
Randomized Phase 2 Trial of APL-2 with Pembrolizumab vs. APL-2 with Pembrolizumab and Bevacizumab vs. Bevacizumab alone in Patients with Recurrent Ovarian Cancer and Persistent Malignant Effusion
… Ovarian Cancer and Persistent Malignant Effusion II Zsiros, Emese This phase II trial studies the effect of APL-2 …